Assembly Biosciences(US:ASMB)2025-03-20 20:10Financial Performance - Assembly Biosciences reported cash, cash equivalents, and marketable securities of $112.1 million as of December 31, 2024, compared to $130.2 million as of December 31, 2023[7]. - Revenues from collaborative research increased to $28.5 million for the year ended December 31, 2024, up from $7.2 million in 2023, primarily due to a full year of revenue recognition under the collaboration with Gilead[7]. - Research and development expenses rose to $55.9 million in 2024, compared to $48.9 million in 2023, reflecting an increase in candidates under development[7]. - General and administrative expenses decreased to $18.0 million in 2024 from $22.9 million in 2023, mainly due to reductions in legal and non-cash stock-based compensation expenses[7]. - The net loss attributable to common stockholders was $40.2 million, or $6.69 per share, for the year ended December 31, 2024, compared to a net loss of $61.2 million, or $13.38 per share, in 2023[7]. - Total liabilities decreased to $85.8 million as of December 31, 2024, from $95.7 million in 2023[12]. Clinical Development - Positive Phase 1a interim data for ABI-1179 indicated it was well-tolerated, supporting potential once-weekly oral dosing at a low dose[3]. - ABI-4334 demonstrated a mean decline in HBV DNA of 2.9 log10 IU/mL in the initial 150 mg dose cohort, primarily in HBeAg negative participants[3]. - Assembly Biosciences plans to run concurrent studies for ABI-5366 and ABI-1179, with interim efficacy data expected in fall 2025[7]. - The company received approximately $20.1 million in equity investment and $10 million in accelerated funding from Gilead to advance clinical development programs[3].